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OGA heterozygosity suppresses intestinal tumorigenesis in
Apcmin/þ mice
YR Yang1, H-J Jang1,2, S Yoon1, YH Lee1, D Nam1, IS Kim1, H Lee3, H Kim4, JH Choi1, BH Kang1, SH Ryu2 and P-G Suh1
Emerging evidence suggests that aberrant O-GlcNAcylation is associated with tumorigenesis. Many oncogenic factors are
O-GlcNAcylated, which modulates their functions. However, it remains unclear how O-GlcNAcylation and O-GlcNAc cycling
enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), affect the development of cancer in animal models. In this study,
we show that reduced level of OGA attenuates colorectal tumorigenesis induced by Adenomatous polyposis coli (Apc) mutation.
The levels of O-GlcNAcylation and O-GlcNAc cycling enzymes were simultaneously upregulated in intestinal adenomas from mice,
and in human patients. In two independent microarray data sets, the expression of OGA and OGT was signiﬁcantly associated with
poor cancer-speciﬁc survival of colorectal cancer (CRC) patients. In addition, OGA heterozygosity, which results in increased levels of
O-GlcNAcylation, attenuated intestinal tumor formation in the Apcmin/þ background. Apcmin/þ OGAþ / mice exhibited a
signiﬁcantly increased survival rate compared with Apcmin/þ mice. Consistent with this, Apcmin/þ OGAþ / mice expressed lower
levels of Wnt target genes than Apcmin/þ . However, the knockout of OGA did not affect Wnt/b-catenin signaling. Overall, these
ﬁndings suggest that OGA is crucial for tumor growth in CRC independently of Wnt/b-catenin signaling.
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INTRODUCTION
O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) are enzymes
that regulate the addition and removal of monosaccharides of
O-linked b-N-acetylglucosamine to the Ser and Thr residues (O-
GlcNAc) of target proteins, respectively.1 Increasing evidence
suggests that OGT and/or OGA expression and O-GlcNAc levels
are altered in different types of cancer, including colon, lung,2
breast,3,4 liver,5 prostate,6,7 pancreas8 and bladder.9 Furthermore,
tumor aggressiveness is closely associated with the levels of
O-GlcNAcylation, OGT and/or OGA. Consistent with this, various
O-GlcNAc-modiﬁed proteins are perturbed in tumorigenesis.
For example, O-GlcNAc-modiﬁed proteins are involved in cancer-
relevant processes such as transcriptional regulation, cell prolifera-
tion and the cell cycle.10 The activity of many oncogenic factors,
including c-Myc,11 b-catenin,12 p5313 and FoxM1,14 is regulated by
direct O-GlcNAcylation. In addition, O-GlcNAc cycling is required
for the precise control of the cell cycle, suggesting an essential
role for O-GlcNAc cycling enzymes in cell proliferation.12,15,16
Colorectal cancer (CRC) is the third common cancer worldwide.
Adenomatous polyposis coli (Apc) is a tumor suppressor gene that
is mutated inB80% of sporadic adenomatous polyps and CRCs.17
Mutant APC causes the oncogenic activation of b-catenin. Notably,
b-catenin is directly O-GlcNAcylated. Several studies have
suggested that the O-GlcNAcylation of b-catenin affects its
transcriptional activity and subcellular localization.12,18 Moreover,
higher levels of O-GlcNAcylation and OGT expression are found in
colon tumors than in corresponding non-tumorous mucosal
tissues.2 Although current evidence implicates O-GlcNAcylation
in CRC, it remains unclear exactly how the levels of
O-GlcNAcylation or O-GlcNAc cycling enzymes affect colorectal
tumorigenesis. To evaluate the role of OGA in colorectal
tumorigenesis, we investigated whether OGA heterozygosity
could alter CRC susceptibility in Apcmin/þ mice.
We found that the levels of O-GlcNAcylation and O-GlcNAc
cycling enzymes were elevated simultaneously in human and
mouse colorectal tumors. Increased expression of the O-GlcNAc
enzymes OGT and OGA was correlated signiﬁcantly with poor
survival. Therefore, OGA heterozygosity attenuates colorectal
tumorigenesis in Apcmin/þ mice. Although b-catenin is O-GlcNA-
cylated, elevated levels of O-GlcNAcylation did not affect Wnt/b-
catenin signaling. Taken together, our observation supports the
hypothesis that OGA plays a key role in intestinal tumorigenesis.
RESULTS AND DISCUSSION
Increased O-GlcNAcylation and O-GlcNAc cycling enzymes in
colorectal adenomas
Previous studies have suggested that abnormal levels of
O-GlcNAcylation and O-GlcNAc enzymes are closely linked to
tumorigenesis. However, it is unclear whether O-GlcNAcylation
plays a role in colorectal tumorigenesis in vivo. First, we analyzed
the expression pattern of O-GlcNAcylation and O-GlcNAc cycling
enzymes in CRC tissues from Apcmin/þ mice and human patients.
Colonic homogenates of normal mucosa and adenomas from
Apcmin/þ mice were analyzed by immunoblotting to assess the
levels of O-GlcNAcylation and O-GlcNAc cycling enzymes.
Interestingly, we observed that O-GlcNAcylation was increased
signiﬁcantly (greater than twofold) in colonic adenomas compared
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with normal mucosa (Figures 1a and b). Colonic adenomas also
expressed higher levels of OGT and OGA than normal mucosa
(Figures 1c and d). Consistent ﬁndings were observed in human
patients with CRC (Figures 1e–h). Surprisingly, both OGT and OGA
enzymes were increased simultaneously in colonic adenomas. This
suggests that the upregulation of OGA compensates for the
increased O-GlcNAcylation. Conversely, we also observed an OGA
deletion, which elevates O-GlcNAcylation and downregulates
OGT.15 These results suggest that the abnormally elevated levels
of O-GlcNAcylation and its cycling enzymes are relevant to
colorectal tumorigenesis.
Association of O-GlcNAc cycling enzyme expression with survival
and cancer recurrence in patients with CRC
Because the aberrant expression of OGT and OGA has been
reported in different types of cancer, we assessed whether OGT
and OGA expression exhibits prognostic value in CRC. Two
independent cohorts of CRC patients from the Mofﬁtt Cancer
Center (GSE17536)19 and a Norwegian hospital (Norwegian;
GSE30378)20 were analyzed for the association between OGT
and OGA expression and patient survival and cancer recurrence.
The Mofﬁtt Cancer Center data set reported the disease-speciﬁc
survival times for 177 CRC patients. The gene expression levels of
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Figure 1. The levels of O-GlcNAc cycling enzymes are elevated in mice and human patients with colonic adenomas. (a–c) The levels of OGA
(a), OGT (b) and O-GlcNAc (c) in normal mucosa (N) and Apcmin/þ mouse adenomas (A) were compared by western blotting using the
following antibodies: the anti-OGT and -OGA polyclonal antibodies, which had been generated previously and were used as described,25
O-GlcNAc (RL2) (MA1-072; Thermo Fisher Scientific Inc., Waltham, MA, USA) and anti-b-actin (691001; MP Biomedicals, Santa Ana, CA, USA).
Densitometry was performed to quantify the immunoblots, and the ratios of OGA, OGT and O-GlcNAc to b-actin were determined. (d–f ) The
same experiment was performed with CRC samples isolated from human patients. Densitometry was performed on immunoblots as
described above. Error bars represent the standard deviation (s.d.; n¼ 3). **Po0.005, *Po0.05 (Student’s t-test). The human specimens were
obtained from the Department of Pathology, Yonsei University (Seoul, Korea), and from the Liver Cancer Specimen Bank of the National
Research Resource Bank Program of the Korea Science and Engineering Foundation of the Ministry of Science and Technology. Authorization
for the use of these tissues for research purposes was obtained from the Institutional Review Board of Yonsei University of College of Medicine
(IRB number: 4-2012-0026).
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OGT and OGA had a strong positive correlation (Pearson’s
correlation¼ 0.71; P-value o2.2e 16), supporting the upregula-
tion of these genes in cancer (Figures 1a and e). Expression was
also signiﬁcantly associated with the disease-speciﬁc survival
probability: OGT and OGA had hazard ratios of 2.26 (P¼ 0.00245)
and 2.42 (P¼ 0.0155). Patients with reduced levels of OGT and
OGA exhibited improved survival rates (Figures 2a and b).
OGA heterozygosity reduces the number of intestinal tumors and
increases the survival of Apcmin/þ mice
We next used OGAþ / mice to explore the effect of increased
OGT and OGA expression on colorectal tumorigenesis. Apcmin/þ
mice were crossed with OGAþ / mice. The intestines of OGAþ /
mice showed reduced levels of both OGA and OGT expression
compared with control mice (Figure 3a). We demonstrated
previously that OGA / mice displayed perinatal lethality, and
that OGA / mouse embryonic ﬁbroblasts downregulate OGT,
which might compensate for the increased levels of O-GlcNAcyla-
tion.15 Therefore, OGAþ / mice are the correct model for
assessing the effect of reduced OGT and OGA expression on
colorectal tumorigenesis. A quantitative analysis of tumor burden
revealed a signiﬁcant twofold reduction in the number and size of
adenomas in the small intestine of Apcmin/þ OGAþ / compared
with Apcmin/þ mice (Figure 3a). Apcmin/þ OGAþ / mice displayed
fewer and smaller tumors along the intestinal tract (Figures 3b
and c). Apcmin/þ OGAþ / mice exhibited a signiﬁcantly increased
survival rate compared with Apcmin/þ mice, and all Apcmin/þ mice
died within 8 months. In contrast, Apcmin/þ OGAþ / mice
showed dramatically increased survival rates (Figure 3d).
Decreased levels of Wnt target genes in Apcmin/þ OGAþ / mice
Based on the attenuated intestine tumor formation in Apcmin/þ
OGAþ / mice, we next analyzed molecular changes. We
examined whether OGA heterozygosity affects the expression
of known Wnt/b-catenin target genes, which are upregulated in
APC-mediated intestinal tumors. Nine genes were decreased in
Apcmin/þ OGAþ / intestines compared with Apcmin/þ intestines
(Figure 3e). We observed that the Wnt target genes Axin2 and Jun
were not signiﬁcantly changed in 8-week-old Apcmin/þ OGAþ /
mice compared with age-matched Apcmin/þ controls. However,
dramatically reduced expression of Axin2 and Jun was observed in
16- and 24-week-old animals (Figures 3f and g). These results
suggest that, although reduced OGA levels do not inﬂuence APC-
mediated tumor initiation, OGA plays critical roles in tumor
growth. Indeed, OGA-deﬁcient cells exhibit a reduced growth
rate.15 In addition, OGT knockdown attenuates the growth of
breast,14 lung and colon cancer cells.2 These results suggest that
reduced OGT and OGA levels disrupt the dynamic regulation of
O-GlcNAcylation, which attenuates cell growth.
OGA disruption does not affect Wnt/b-catenin signaling
The activation of b-catenin is essential not only for tumor initiation
but also for tumor progression in Apcmin/þ mice.21 Importantly,
b-catenin is directly O-GlcNAcylated, and we also observed that
b-catenin is modiﬁed with O-GlcNAc (Figure 4a). The O-GlcNAcyla-
tion of b-catenin regulates its localization and transcriptional
activity.22 OGT interacts with b-catenin to regulate cyclin D1
synthesis upon serum stimulation.12 Therefore, we assessed
whether OGA deﬁciency affects Wnt/b-catenin signaling. The
deletion of OGA did not affect Wnt3-mediated b-catenin
accumulation (Figure 4b). In addition, there were no signiﬁcant
differences in Axin2 and Jun mRNA levels between OGAþ /þ and
OGA / mouse embryonic ﬁbroblasts after stimulation with
Wnt3a (Figure 4c). We also used immunoblotting and quantitative
PCR to further conﬁrm that the OGA inhibitor Thiamet G and
knockdown did not affect Wnt/b-catenin signaling (Figures 4d and
e). Increased O-GlcNAcylation after Thiamet G treatment might
result in the upregulation OGA to compensate for the increased
O-GlcNAcylation. This observation supports the results presented
in Figure 3a. These results suggest that OGA heterozygosity
affects tumorigenesis independently of Wnt/b-catenin signaling.
In addition, intestinal tumorigenesis correlates with OGT and OGA
levels, which are important for the dynamic regulation of
O-GlcNAcylation.
CONCLUSIONS
Many studies have suggested that elevated O-GlcNAcylation
and/or O-GlcNAc cycling enzymes contribute to tumorigenesis.
In colon cancer, the levels of O-GlcNAc and OGT are increased.23
However, it remains unclear whether the elevated
O-GlcNAcylation caused by increased OGT activity promotes
tumorigenesis in vivo. Here, we suggested a critical role for
O-GlcNAc cycling enzymes in colorectal tumorigenesis. We
observed that human colonic adenomas exhibit elevated
O-GlcNAcylation, and increased levels of both OGT and OGA.
Interestingly, an analysis of microarray data sets revealed that
OGA and OGT expression was correlated. This supports the
immunoblotting data, which showed simultaneously increased
OGT and OGA in colonic adenomas. Importantly, OGT and OGA
are both correlated with survival and cancer recurrence in patients
with CRC. Our results demonstrate that OGA heterozygosity
reduces APC-mediated colorectal tumorigenesis and enhances the
survival of OGA heterozygous mice in the Apcmin/þ background.
Figure 2. Association of the expression levels of O-GlcNac cycling enzymes with CRC patient survival and relapse. (a) The MCC cohort was
divided into two groups according to O-GlcNac enzyme levels, and the Kaplan–Meier curves of disease-specific survival were compared.
(b) The Norwegian patient cohort was divided into two groups according to O-GlcNac enzyme levels, and the Kaplan–Meier curves of relapse-
free survival were compared. The split with the lowest P-value in the log-rank test was selected from among the median 60% of samples sorted
by gene expression levels. The hazard ratios and P-values shown in the plots were calculated from Cox’s proportional-hazard regression model.
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Wnt target genes were downregulated in Apcmin/þ OGAþ / mice
compared with Apcmin/þ controls. Although b-catenin is directly
O-GlcNAcylated, elevated O-GlcNAcylation did not affect Wnt/
b-catenin signaling in vitro. Although O-GlcNAcylation is elevated
in colonic adenomas, we observed reduced tumorigenesis in
OGAþ / mice, in which O-GlcNAcylation is constantly elevated.
These results suggest that the levels of OGA and OGT are critical
for colorectal tumorigenesis. These results support previous
studies showing that the knockdown of OGA or OGT reduced
cell growth in vitro.14,15 This suggests that reduced levels of OGT
and OGA do not properly regulate dynamic O-GlcNAcylation,
which inﬂuences the functions of O-GlcNAc target proteins.
Nevertheless, the mechanism by which OGA heterozygosity
attenuates tumorigenesis remains unclear. However, many
studies have suggested that aberrant O-GlcNAcylated proteins
contribute to the disruption of cancer cell growth. Notably, many
transcription factors, including c-Myc, p53, NF-kB, SP1, FoxM1
and HCF-1, are O-GlcNAcylated.24 O-GlcNAcylation modulates
their activity or stability, which affects cancer cell growth.
Phosphorylation is regulated by a variety of protein kinases
and phosphatases. Although O-GlcNAcylation is similar to
phosphorylation, unlike phosphorylation it is regulated by only
OGT and OGA, which are encoded by single genes. Therefore,
reduced levels of O-GlcNAc cycling enzymes cause various
changes in the activity of entire target proteins. Furthermore,
reduced levels of OGT and OGA might not normally regulate
dynamic O-GlcNAcylation during the cell cycle, which is required
for cell cycle control.15,16 We conclude that O-GlcNAc enzymes are
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Figure 3. OGA heterozygosity attenuates APC-mediated intestinal tumorigenesis. (a) The expression of OGA was confirmed in OGAþ /
intestines. O-GlcNAc levels were elevated, and OGT was downregulated in OGAþ / intestines. (b) The number (left) and size (right) of
intestinal tumors. (c) Gross appearance of the small intestine (upper), and hematoxylin and eosin staining (lower) of intestinal adenoma
sections from Apcmin/þ and Apcmin/þ OGAþ / mice at 20 weeks. n¼ 8 mice per group. Error bars represent ±s.e.m. **Po0.005, *Po0.05
(Student’s t-test). (d) Survival rate of Apcmin/þ and Apcmin/þ OGAþ / mice (Kaplan–Meier log-rank, P¼ 0.0001, n¼ 24 and n¼ 15, respectively).
Apcmin/þ mice n¼ 24; Apcmin/þ OGAþ / mice n¼ 15. (e) The mRNA levels of Wnt target genes were analyzed using RT2 Profiler PCR Arrays
(Qiagen, Valencia, CA, USA). Mice were killed at 8, 16 or 20 weeks and the mRNA levels of (f ) Axin2 and (g) Jun were analyzed by qPCR. The
primer sequences (mouse) used were: Axin2 forward, 50-ACTCTGGAGGCTTTCGTTTG-30; Axin2 reverse, 50-TTAAGTCAGCAGGGGCTCAT-30; Jun
forward, 50-CCTTCTACGACGATGCCCTC-30 ; Jun reverse, 50-GGTTCAAGGTCATGCTCTGTTT-30; GAPDH forward, 50-AGGTCGGTGTGAACGGATTTG-
30; and GAPDH reverse, 50-TGTAGACCATGTAGTTGAGGTCA-30. Error bars represent the s.d. (n¼ 3); **Po0.005, *Po0.05 (Student’s t-test).
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essential for tumor growth in CRC, and that targeting OGA may
help suppress the intestinal tumorigenesis initiated by Apc
mutation.
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